Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

MDxHealth nieuws 2018

3.273 Posts
Pagina: «« 1 ... 24 25 26 27 28 ... 164 »» | Laatste | Omlaag ↓
  1. Bertussie 8 februari 2018 10:11
    quote:

    BassieNL schreef op 8 februari 2018 09:28:

    Dat is op de OTC markt, daar kun je niet zomaar op handelen
    1500 stuks is heel wat, vergeleken met andere handelsdagen.
    Snel weer vergeten!

    Als 1500 stuks op de OTC markt staat tot 1:1 dan lijkt me dat niet veel
    Of gaat dat per 1: 100 ?
  2. forum rang 6 Tom3 9 februari 2018 17:57
    quote:

    Superdude schreef op 6 februari 2018 21:43:

    This automation step will help us to handle the increasing volumes and QC requirements in both our certified laboratories in Europe and the US. It will also provide our SelectMDx IVD customers with an advanced software they can use support and standardize drafting of result reports,” said Dr. Jan Groen, CEO at MDxHealth.
    Heb je een link? Lijkt me op zich goed nieuws.
  3. Bezint eer ge begint 10 februari 2018 10:04
    is dat hier al gepost?

    UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
    Jan 23, 2018 | staff reporter
    NEW YORK (GenomeWeb) – UgenTec announced today a partnership to develop artificially intelligent software to support interpretation of molecular test results for MDxHealth's ConfirmMDx and SelectMDx for prostate cancer tests.

    MDxHealth's SelectMDx test is a liquid biopsy test that identifies patients with an increased risk for clinically significant prostate cancer. The firm's ConfirmMDx is a tissue biopsy test that allows patients to forgo unnecessary repeat biopsy procedures.

    "[This automation step] will… also provide our SelectMDx IVD customers with an advanced software they can use [to] support and standardize drafting of result reports," MDxHealth CEO Jan Groen said in a statement.

    Financial and other terms of the agreement were not disclosed.

    In December, UgenTec expanded a collaboration with Fast Track Diagnostics to include artificially intelligent PCR software on FTR's kits.
  4. rodi116 12 februari 2018 10:28
    quote:

    Bezint eer ge begint schreef op 10 februari 2018 10:04:

    is dat hier al gepost? Yep

    UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
    Jan 23, 2018 | staff reporter
    NEW YORK (GenomeWeb) – UgenTec announced today a partnership to develop artificially intelligent software to support interpretation of molecular test results for MDxHealth's ConfirmMDx and SelectMDx for prostate cancer tests.

    MDxHealth's SelectMDx test is a liquid biopsy test that identifies patients with an increased risk for clinically significant prostate cancer. The firm's ConfirmMDx is a tissue biopsy test that allows patients to forgo unnecessary repeat biopsy procedures.

    "[This automation step] will… also provide our SelectMDx IVD customers with an advanced software they can use [to] support and standardize drafting of result reports," MDxHealth CEO Jan Groen said in a statement.

    Financial and other terms of the agreement were not disclosed.

    In December, UgenTec expanded a collaboration with Fast Track Diagnostics to include artificially intelligent PCR software on FTR's kits.

    www.ugentec.com/blog/press-release-ug...
3.273 Posts
Pagina: «« 1 ... 24 25 26 27 28 ... 164 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.